DHA Supplementation in Preterm Infants Boosts Blood Fatty Acid Levels, Study Finds

A new study published in Pediatric Research on 5 June 2026 examines how enteral DHA supplementation affects blood fatty acid levels in preterm infants. The findings highlight significant changes in DHA concentrations, offering potential benefits for neurodevelopment and inflammation control in vulnerable newborns. Researchers administered docosahexaenoic acid (DHA) enterally to preterm infants and monitored its effects over time. The results showed a marked increase in blood DHA levels compared to infants who did not receive supplementation. These elevated levels remained stable throughout the study, indicating sustained neurodevelopmental support.

The study also revealed broader metabolic shifts. DHA influenced other fatty acid groups, suggesting a complex interaction within lipid pathways. Notably, the balance between omega-6 and omega-3 fatty acids improved, which may help reduce chronic inflammation in preterm babies. Beyond structural roles in brain development, DHA acts as a precursor for anti-inflammatory compounds. The enteral delivery method proved both practical and well-tolerated in this fragile population. By analysing detailed fatty acid profiles, the team uncovered unique metabolic patterns in preterm infants, reinforcing the case for tailored neonatal nutrition. The controlled design of the study accounted for confounding variables, strengthening the reliability of the data. This rigour supports the potential translation of findings into clinical care, where DHA-enriched feeds could enhance brain substrate availability and long-term cognitive outcomes.

The research demonstrates that enteral DHA supplementation boosts and maintains blood DHA levels in preterm infants. It also modulates broader fatty acid metabolism, potentially easing inflammation and supporting brain development. These insights pave the way for personalised nutrition strategies aimed at improving health outcomes in preterm newborns.